Balt USA
Balt USA is the US arm of Balt SAS, a French-founded neurovascular medical device company that designs, manufactures and sells catheters, stents, flow diverters and embolic agents used by hospitals and interventional neuroradiologists to treat stroke, aneurysms and vascular malformations.
- Company typePrivate
- Founded1977
- HeadquartersIrvine, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Balt USA does
Balt USA is the US operating arm of Balt SAS, a French-founded neurovascular medical device company established in 1977 and headquartered in Montmorency, France, with its US hub in Irvine, California. The company develops, manufactures and sells interventional devices for the endovascular treatment of hemorrhagic and ischemic stroke, intracranial aneurysms, arteriovenous malformations and peripheral embolization procedures. Balt USA positions itself as operating the industry's broadest neurovascular product portfolio, spanning flow-diverting stents (Silk Vista), braided intracranial stents (LEO+), flow-directed microcatheters (MAGIC), aspiration catheters (Raptor), dual-lumen balloon microcatheters (Eclipse 2L), detachable coils (Optima) and the Squid non-adhesive liquid embolic agent.
The group manufactures its devices in Montmorency (France), Bonn (Germany) and now Irvine (California), and has spent the past several years transitioning from distributor-led to direct-sales operations in major markets — converting Italy (2021), Australia/New Zealand (2024) and Canada (2025) via acquisitions, while opening new direct offices in Boston (2021), Paris (2022), Bogotá (2025) and Beijing (2026). The US is the single largest market, accounting for 31% of group revenue, and the company has committed $400 million in additional US investment through SelectUSA (May 2026), including a second Irvine facility.
The business model is a standard B2B medical-device model: devices are sold directly to hospitals and neurointerventional physicians through a field sales force and clinical specialist team. Pricing is not publicly disclosed but is contractually negotiated with hospital systems, typically under GPO or IDN framework agreements. Revenue is essentially 100% recurring from hardware unit sales; no software, subscription, imaging, or service revenue streams are disclosed. The company has not publicly reported consolidated revenue, profitability or valuation, but disclosed capital actions — including a €355 million debt refinancing in December 2024 — are consistent with a mid-cap commercial-stage medical device issuer.
Balt USA firmographics
Firmographics- Name
- Balt USA
- Legal name
- BALT SAS
- Website
- https://baltgroup.com
- Company type
- Private
- Founded year
- 1977
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Balt USA is the US arm of Balt SAS, a French-founded neurovascular medical device company that designs, manufactures and sells catheters, stents, flow diverters and embolic agents used by hospitals and interventional neuroradiologists to treat stroke, aneurysms and vascular malformations.
- Ownership category
- akta.pro rank
Balt USA industry classification
Industry- Product category
- Neurovascular Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
Keywords
Where Balt USA is headquartered
LocationHeadquarters
- HQ city
- Irvine
- HQ country
- United States
- HQ region
- North America
Offices17 records
Markets served
Balt USA business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Medical Device Sales: Balt generates revenue through the sale of neurovascular and peripheral vascular medical devices including catheters, stents, coils, flow diverters, and liquid embolic agents to hospitals and healthcare providers globally.
- US Market Revenue: Since establishing US presence in 2016, the US market has grown to represent 31% of total company revenue.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
Balt USA product offering
Product offeringCore offering
Balt develops, manufactures, and sells neurovascular and peripheral vascular medical devices for the treatment of ischemic and hemorrhagic stroke, intracranial aneurysms, and peripheral embolization procedures. The portfolio includes aspiration catheters, self-expandable braided intracranial stents, flow diverters, liquid embolic agents, double-lumen balloon catheters, flow-directed microcatheters, long sheaths, coil systems, occlusion coils, micro guidewires, and delivery catheters. Products are sold directly to hospitals and neurointerventional radiologists through wholly-owned subsidiaries in 16 countries.
Differentiator
Problem solved
Functional benefit
Brands
- Balt Prime: Educational platform providing comprehensive suite of educational videos, communication with industry experts, and curated experience for specific therapy areas
- Squid
- CatchView
- LEO+
- Silk Vista
- Ballast
- Raptor
- Optima
- MAGIC
Products and services
- Squid Liquid Embolic Agent EVOH co-polymer (ethylene vinyl alcohol) liquid embolic with micronized Tantalum powder; available in 12 cP, 18 cP and 34 cP viscosity offerings. Used by neurointerventional radiologists for embolization procedures, including the first FDA-approved indication for MMA embolization as adjunct treatment for chronic subdural hematomas.
- Ballast 088 Long Sheath Long sheath indicated for the introduction of interventional devices into the peripheral, coronary, and neurovasculature. Sold to hospitals and neurointerventional radiologists.
- Catchview Revascularization Device Stent-retriever device for mechanical thrombectomy in ischemic stroke treatment. For neurointerventional radiologists performing revascularization procedures.
- Carrier Delivery Catheter Delivery catheter for neurovascular interventional procedures.
- Copernic RC Venous Remodelling Balloon Venous remodelling balloon for vascular interventional procedures.
- Eclipse 2L Double Lumen Balloon Catheter Double lumen balloon catheter with a flat catheter design featuring two separate lumens (inflation tube and infusion catheter). Enables inflation/deflation while navigating and allows for balloon-assisted embolization.
- Fargo Guiding Sheath Guiding sheath for neurovascular access (product name truncated in source; included as a distinct product family on the Balt products page).
- LEO+ Self-Expandable Braided Intracranial Stent Self-expandable intracranial stent with 16 braided wires providing coil mass support, radial force, and neck coverage; features two platinum helical markers and is fully resheathable. Used by neurointerventionalists for aneurysm treatment.
- MAGIC Flow-Directed Microcatheter Blood flow dependent microcatheter for navigation inside distal neuro and peripheral vasculature. Used by neurointerventional radiologists for embolization and other procedures.
- Optima Coil System Coil system for embolization procedures used in neurovascular and peripheral vascular interventions.
- OptiBlock Vessel Occlusion Coil Novel vessel occlusion coil for embolization procedures.
- Raptor Aspiration Catheter Aspiration catheter available in 0.071" and 0.074" inner diameter with optimized OD compatibility; features 60cm hydrophilic coating and a 20cm coil-only distal segment for navigation. Designed for revascularization in acute ischemic stroke.
- Silk Vista Flow Diverter New generation flow diverter stent for treatment of intracranial aneurysms. CE Mark received July 2020.
- Silk Vista Baby Flow Diverter Flow diverter compatible with .017 catheter for treatment of intracranial aneurysms.
- HYBRID .007 Micro Guidewire .007 micro guidewire for neurovascular interventions.
- Balt Prime Educational Platform Educational platform providing a comprehensive suite of educational videos, communication with industry experts, and curated experience for specific therapy areas. Targeted at neurointerventional radiologists and neurosurgeons.
Quantifiable outcome
- Significant reduction in treatment failure rates without increasing adverse events in cSDH patients treated with Squid liquid embolic (STEM Trial, NEJM)
- +1 more outcomes
Companies that use Balt USA
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Balt USA technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Balt USA partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- US Government (SelectUSA)coreBalt announced $400 million US investment commitment at SelectUSA Investment Summit 2026 with attendance by Under Secretary of Commerce William Kimmitt, US Embassy Paris officials, GO-Biz Chief Deputy Director, and City of Irvine Economic Development Director.
- Yocan Medical Systems (Canada)minorAcquisition of Canadian distributor Yocan Medical Systems to establish Balt Canada Ltd for direct operations in North America.
- Stéphane DiaganaminorPartnership with former World and European Champion in 400m hurdles and World Champion in 4x400m relay as brand ambassador to promote stroke prevention through physical activity. Diagana appeared on RMC radio and published an op-ed in Le Figaro mentioning Balt on World Stroke Day.
Scale indicators9 records
Recent moves12 records
Expansion highlights6 records
Balt USA competitors and assessment
Company assessmentBroad incumbents
- Stryker: Stryker operates a major neurovascular business (via its Neurovascular division) competing directly with Balt across coils, stents, and flow diverters. As a much larger diversified medtech incumbent, Stryker offers overlapping capabilities within a broader portfolio and is a primary direct competitor in stroke intervention.
- Cerenovus (Johnson & Johnson): Cerenovus is J&J's neurovascular division offering coils, flow diverters, and embolization products that compete across Balt's portfolio. As a unit of a diversified healthcare giant, Cerenovus brings deeper R&D and commercialization resources while specializing in the same neurovascular space.
- Medtronic: Medtronic's Neurovascular portfolio (including the Solitaire stent retriever) competes head-to-head with Balt's CatchView and other devices. As a global medtech incumbent, Medtronic brings deeper hospital relationships and broader commercial reach than Balt in the US neurointerventional market.
Direct peers
- MicroVention (Terumo): MicroVention, part of Terumo, offers coils, flow diverters (FRED), and liquid embolics that compete directly with Balt's portfolio in aneurysm and stroke treatment. Both companies focus exclusively on neurovascular devices, making them close functional and customer-base peers.
- Penumbra: Penumbra specializes in aspiration thrombectomy systems (Penumbra System, Indigo) that compete directly with Balt's Raptor aspiration catheter in acute ischemic stroke. The companies overlap closely in product category, target customers (neurointerventional radiologists), and core neurovascular therapy area.
Regional players
- Acandis GmbH: Acandis is a German neurovascular specialist offering stents, flow diverters, and thrombectomy devices. It overlaps with Balt's product range but has a more regional (DACH/EMEA) footprint with limited US sales operations.
- phenox GmbH: phenox is a German neurovascular device company offering stent retrievers, flow diverters, and coils. It is comparable to Balt in product breadth and focus, but primarily serves the European market with less US commercial presence.
Emerging players
- Rapid Medical: Rapid Medical is an emerging neurovascular company developing adjustable stent retrievers and access devices for stroke intervention. It overlaps with Balt's CatchView and Ballast products in ischemic stroke treatment but at a smaller commercial scale.
- Wallaby Medical: Wallaby Medical (formerly Wallaby Phenox merger) is an emerging neurovascular company with stent retrievers and access devices. It competes in select Balt product categories (stent retriever, delivery catheters) and represents a fast-growing Asia-Pacific-rooted peer.
- Inari Medical: Inari Medical focuses on venous thromboembolism and peripheral vascular intervention with FlowTriever and ClotTriever systems. While not a direct neurovascular competitor, it overlaps with Balt's emerging peripheral embolization strategy and similar specialty medtech commercial model.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Balt USA social profiles
Digital presenceBalt USA financial estimates
Financial estimateRevenue estimate
Valuation estimate
Balt USA leadership team
Management profileNumber of profiles
Profiles10 records
Balt USA subsidiaries and ownership
Company hierarchySubsidiaries5 records
Balt USA funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Balt USA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Balt USA
What does Balt USA do?
Balt develops, manufactures, and sells neurovascular and peripheral vascular medical devices for the treatment of ischemic and hemorrhagic stroke, intracranial aneurysms, and peripheral embolization procedures. The portfolio includes aspiration catheters, self-expandable braided intracranial stents, flow diverters, liquid embolic agents, double-lumen balloon catheters, flow-directed microcatheters, long sheaths, coil systems, occlusion coils, micro guidewires, and delivery catheters. Products are sold directly to hospitals and neurointerventional radiologists through wholly-owned subsidiaries in 16 countries.
Is Balt USA a public or private company?
Balt USA is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Balt USA founded?
Balt USA was founded in 1977. It employs 501 to 1,000 people.
Where is Balt USA based?
Balt USA is headquartered in Irvine, United States, in the North America region.
How does Balt USA make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are US Market Revenue.
Who are Balt USA's main competitors?
Broad incumbents on record are Stryker, Cerenovus (Johnson & Johnson) and Medtronic. Direct peers are MicroVention (Terumo) and Penumbra. Regional players are Acandis GmbH and phenox GmbH. Emerging players are Rapid Medical, Wallaby Medical and Inari Medical.
Does Balt USA have an API?
No public API is recorded for Balt USA.
What industry is Balt USA in?
Balt USA's product category is Neurovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 339112 and its SIC code is 3841.